Biodesix and Addario Lung Cancer Medical Institute initiate study to predict overall survival using checkpoint immunotherapy for lung cancer patients

BOULDER and SAN CARLOS, Calif. -- Addario Lung Cancer Medical Institute (ALCMI) and Biodesix, Inc. today announced they will begin an observational study to prospectively evaluate the clinical... Read More

Tuesday September 1, 2020 0 comments Tags: Boulder, Biodesix, Addario Lung Cancer Medical Institute, Scott Hutton